Patient baseline demographic and disease characteristics
| Parameter . | Patients with CLL (N = 167) . |
|---|---|
| Age, median (IQR), y | 71.0 (63.0-76.0) |
| Age ≤65 y, N (%) | 50 (29.9) |
| Male sex, N (%) | 112 (67.1) |
| Disease/treatment status, N (%) | |
| Treatment-naive | 58 (34.7) |
| On-therapy | 75 (44.9) |
| Off-therapy in remission | 24 (14.4) |
| Off-therapy in relapse | 10 (6.0) |
| Binet stage,* N (%) | |
| A | 43 (64.1) |
| B | 14 (20.9) |
| C | 10 (14.9) |
| IGHV mutational status, N (%) | |
| Mutated | 61 (50.0) |
| Unmutated | 61 (50.0) |
| FISH, N (%) | |
| Normal | 20 (12.0) |
| del(13q) | 39 (23.4) |
| Trisomy 12 | 16 (9.6) |
| del(11q) | 31 (18.6) |
| del(17p) | 19 (11.4) |
| β2-microglobulin, N (%) | |
| ≤3.5 mg/L | 90 (78.3) |
| >3.5 mg/L | 25 (21.7) |
| Protocols of currently treated, N (%) | |
| BTKis | 50 (66.7) |
| Venetoclax ± anti-CD20 antibody | 22 (29.3) |
| Others | 3 (4.0) |
| Time from last anti-CD20 antibody to vaccination, N (%) | |
| <12 mo | 22 (28.6) |
| ≥12 mo | 55 (71.4) |
| Laboratory parameters, median (IQR) | |
| Absolute lymphocyte count, (109/L) | 5.0 (2.0-18.5) |
| β2-microglobulin, mg/L | 2.5 (2.0-3.5) |
| IgG, mg/dL | 723.5 (515.8-1000.3) |
| IgM, mg/dL | 32.0 (0.0-57.5) |
| IgA, mg/dL | 94.0 (49.0-146.8) |
| Parameter . | Patients with CLL (N = 167) . |
|---|---|
| Age, median (IQR), y | 71.0 (63.0-76.0) |
| Age ≤65 y, N (%) | 50 (29.9) |
| Male sex, N (%) | 112 (67.1) |
| Disease/treatment status, N (%) | |
| Treatment-naive | 58 (34.7) |
| On-therapy | 75 (44.9) |
| Off-therapy in remission | 24 (14.4) |
| Off-therapy in relapse | 10 (6.0) |
| Binet stage,* N (%) | |
| A | 43 (64.1) |
| B | 14 (20.9) |
| C | 10 (14.9) |
| IGHV mutational status, N (%) | |
| Mutated | 61 (50.0) |
| Unmutated | 61 (50.0) |
| FISH, N (%) | |
| Normal | 20 (12.0) |
| del(13q) | 39 (23.4) |
| Trisomy 12 | 16 (9.6) |
| del(11q) | 31 (18.6) |
| del(17p) | 19 (11.4) |
| β2-microglobulin, N (%) | |
| ≤3.5 mg/L | 90 (78.3) |
| >3.5 mg/L | 25 (21.7) |
| Protocols of currently treated, N (%) | |
| BTKis | 50 (66.7) |
| Venetoclax ± anti-CD20 antibody | 22 (29.3) |
| Others | 3 (4.0) |
| Time from last anti-CD20 antibody to vaccination, N (%) | |
| <12 mo | 22 (28.6) |
| ≥12 mo | 55 (71.4) |
| Laboratory parameters, median (IQR) | |
| Absolute lymphocyte count, (109/L) | 5.0 (2.0-18.5) |
| β2-microglobulin, mg/L | 2.5 (2.0-3.5) |
| IgG, mg/dL | 723.5 (515.8-1000.3) |
| IgM, mg/dL | 32.0 (0.0-57.5) |
| IgA, mg/dL | 94.0 (49.0-146.8) |
FISH, fluorescence in situ hybridization.
Treatment-naive patients and patients in relapse.